Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Détails

ID Serval
serval:BIB_558CD2425591
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Radiotherapy combination opportunities leveraging immunity for the next oncology practice.
Périodique
CA: a cancer journal for clinicians
Auteur(s)
Herrera F.G., Bourhis J., Coukos G.
ISSN
1542-4863 (Electronic)
ISSN-L
0007-9235
Statut éditorial
Publié
Date de publication
01/2017
Peer-reviewed
Oui
Volume
67
Numéro
1
Pages
65-85
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or recurrent tumors receive radiotherapy (RT), with the explicit goal of eliminating tumors through direct killing. The current RT dose and schedule regimens have been empirically developed. Although early clinical studies revealed that RT could provoke important responses not only at the site of treatment but also on remote, nonirradiated tumor deposits-the so-called "abscopal effect"- the underlying mechanisms were poorly understood and were not therapeutically exploited. Recent work has elucidated the immune mechanisms underlying these effects and has paved the way for developing combinations of RT with immune therapy. In the wake of recent therapeutic breakthroughs in the field of immunotherapy, rational combinations of immunotherapy with RT could profoundly change the standard of care for many tumor types in the next decade. Thus, a deep understanding of the immunologic effects of RT is urgently needed to design the next generation of therapeutic combinations. Here, the authors review the immune mechanisms of tumor radiation and summarize the preclinical and clinical evidence on immunotherapy-RT combinations. Furthermore, a framework is provided for the practicing clinician and the clinician investigator to guide the development of novel combinations to more rapidly advance this important field. CA Cancer J Clin 2017;67:65-85. © 2016 American Cancer Society.

Mots-clé
Animals, Antigens, Neoplasm/immunology, Combined Modality Therapy, Humans, Immunotherapy/methods, Neoplasm Metastasis/immunology, Neoplasm Metastasis/radiotherapy, Neoplasms/immunology, Neoplasms/radiotherapy, Radiotherapy Dosage
Pubmed
Création de la notice
16/09/2016 18:48
Dernière modification de la notice
20/08/2019 14:10
Données d'usage